• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经典型和滤泡型乳头状甲状腺癌的组织病理学特征及预后比较

Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.

作者信息

Tunca F, Sormaz I C, Iscan Y, Senyurek Y G, Terzioglu T

机构信息

Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, İstanbul Tıp Fakültesi Genel Cerrahi Anabilim Dalı, Turgut Özal Cad., 34390, Fatih/Istanbul, Turkey.

Department of General Surgery, Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey.

出版信息

J Endocrinol Invest. 2015 Dec;38(12):1327-34. doi: 10.1007/s40618-015-0376-6. Epub 2015 Aug 18.

DOI:10.1007/s40618-015-0376-6
PMID:26280320
Abstract

PURPOSE

To compare the histopathological features and the outcomes of the follicular variant and classical variant of papillary thyroid carcinoma.

MATERIAL AND THE METHODS

Demographic data, histopathological features (tumor size, thyroid capsule invasion, extrathyroidal extension, vascular invasion and multicentricity), lymph node metastasis, local recurrence, distant metastasis and mortality during the follow-up of 258 C-PTC and 153 FVPTC patients who underwent total thyroidectomy were compared. The dynamic risk assessment system was used to refine postoperative risk estimates based on the assessment of response to initial treatment.

RESULTS

The demographic data showed no significant difference between the two groups. The mean tumor size showed no significant difference between the two groups. The rate of thyroid capsule invasion, extrathyroidal extension, and lymph node metastasis was significantly higher in C-PTC than in FVPTC group, whereas multicentricity and bilobar involvement were significantly higher in FVPTC group than in C-PTC group. Central lymph node metastasis was significantly more frequent in patients with C-PTC than in those with FVPTC (p < 0.0001). Local recurrence was found in 22 (5.3 %) patients overall and was significantly more common in C-PTC group than in FVPTC group. In patients ≥45 years, the local recurrence rate was significantly higher in patients with CPTC than in those with FVPTC. The local recurrence rate in patients <45 years was not significantly different between the two groups of patients. The multicentricity rate was significantly higher in the FVPTC group for both age groups. Dynamic risk assessment showed that the rate of intermediate- and high-risk groups showed no significant difference between C-PTC and FVPTC patients but the rate of low risk patients was higher in FVPTC group than in C-PTC group (p = 0.04). The recurrence rate in low-risk group was found higher in C-PTC compared to FVPTC patients (4.7 vs. 0.7 %, p = 0.04, respectively). The recurrence rate showed no significant difference in both intermediate- and high-risk groups in C-PTC and FVPTC patients. During the follow-up, the rate of distant metastasis and disease-specific mortality was not significantly different between the two groups (p = 0.25).

CONCLUSION

FVPTC is a common subtype of PTC and has a higher rate of multicentricity with bilobar involvement. Although aggressive histopathologic features, such as thyroid capsule invasion, extrathyroidal extension, and lymph node metastasis, are significantly more frequent in CPTC than in FVPTC, the long-term outcome is similar in both subtypes after appropriate initial surgery and postoperative RAI ablation treatment.

摘要

目的

比较甲状腺乳头状癌滤泡变异型和经典变异型的组织病理学特征及预后。

材料与方法

比较258例接受全甲状腺切除术的经典型甲状腺乳头状癌(C-PTC)患者和153例滤泡型甲状腺乳头状癌(FVPTC)患者的人口统计学数据、组织病理学特征(肿瘤大小、甲状腺被膜侵犯、甲状腺外侵犯、血管侵犯和多中心性)、淋巴结转移、局部复发、远处转移及随访期间的死亡率。采用动态风险评估系统,根据对初始治疗反应的评估来优化术后风险估计。

结果

两组的人口统计学数据无显著差异。两组的平均肿瘤大小无显著差异。C-PTC组的甲状腺被膜侵犯、甲状腺外侵犯及淋巴结转移率显著高于FVPTC组,而FVPTC组的多中心性和双侧叶受累率显著高于C-PTC组。C-PTC患者的中央区淋巴结转移明显比FVPTC患者更常见(p < 0.0001)。总体上22例(5.3%)患者出现局部复发,C-PTC组比FVPTC组更常见。在年龄≥45岁的患者中,C-PTC患者的局部复发率显著高于FVPTC患者。年龄<45岁的两组患者局部复发率无显著差异。两个年龄组中FVPTC组的多中心性率均显著更高。动态风险评估显示,C-PTC和FVPTC患者的中高危组发生率无显著差异,但FVPTC组的低风险患者发生率高于C-PTC组(p = 0.04)。C-PTC患者低风险组的复发率高于FVPTC患者(分别为4.7%和0.7%,p = 0.04)。C-PTC和FVPTC患者的中高危组复发率均无显著差异。随访期间,两组的远处转移率和疾病特异性死亡率无显著差异(p = 0.25)。

结论

FVPTC是PTC的常见亚型,多中心性和双侧叶受累率较高。尽管C-PTC中甲状腺被膜侵犯、甲状腺外侵犯及淋巴结转移等侵袭性组织病理学特征比FVPTC显著更常见,但在进行适当的初始手术和术后放射性碘消融治疗后,两种亚型的长期预后相似。

相似文献

1
Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.经典型和滤泡型乳头状甲状腺癌的组织病理学特征及预后比较
J Endocrinol Invest. 2015 Dec;38(12):1327-34. doi: 10.1007/s40618-015-0376-6. Epub 2015 Aug 18.
2
High Incidence of Distant Metastasis Is Associated With Histopathological Subtype of Pediatric Papillary Thyroid Cancer - a Retrospective Analysis Based on SEER.儿童甲状腺乳头状癌的组织病理学亚型与远处转移的高发生率相关——基于 SEER 的回顾性分析。
Front Endocrinol (Lausanne). 2021 Nov 11;12:760901. doi: 10.3389/fendo.2021.760901. eCollection 2021.
3
Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy.甲状腺乳头状癌的乳头状和滤泡状变体:初始表现及对治疗的反应
Otolaryngol Head Neck Surg. 2005 Jun;132(6):840-4. doi: 10.1016/j.otohns.2005.02.002.
4
Risk factors of distant metastasis in the follicular variant of papillary thyroid carcinoma.甲状腺乳头状癌滤泡变体远处转移的危险因素。
J Formos Med Assoc. 2016 Aug;115(8):665-71. doi: 10.1016/j.jfma.2015.07.002. Epub 2015 Aug 1.
5
Increasing diagnosis of thyroid papillary carcinoma follicular variant in south-east Anatolian region: comparison of characteristics of classical papillary and follicular variant thyroid cancers.在东南安纳托利亚地区,甲状腺乳头状癌滤泡亚型的诊断率不断增加:经典型甲状腺乳头状癌和滤泡亚型甲状腺癌特征的比较。
Endocr Pathol. 2012 Sep;23(3):157-60. doi: 10.1007/s12022-012-9216-9.
6
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.主要甲状腺乳头状癌变体的临床病理差异风险与预后
J Clin Endocrinol Metab. 2016 Jan;101(1):264-74. doi: 10.1210/jc.2015-2917. Epub 2015 Nov 3.
7
Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome.甲状腺乳头状癌的经典型和滤泡变型:临床病理特征及长期预后的比较研究
World J Surg. 2006 May;30(5):752-8. doi: 10.1007/s00268-005-0356-7.
8
Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.滤泡型甲状腺乳头状癌是一种独特的临床实体:基于人群的 10740 例病例研究。
Thyroid. 2013 Oct;23(10):1263-8. doi: 10.1089/thy.2012.0453. Epub 2013 Sep 11.
9
Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer.滤泡型甲状腺乳头状癌患者对侧肿瘤的发生率。
J Am Coll Surg. 2017 Jun;224(6):1021-1027. doi: 10.1016/j.jamcollsurg.2016.12.007. Epub 2016 Dec 23.
10
Risk factors for central neck lymph node metastases in follicular variant vs. classic papillary thyroid carcinoma.滤泡型与经典型甲状腺乳头状癌中央颈部淋巴结转移的危险因素。
Endocrine. 2018 Oct;62(1):64-70. doi: 10.1007/s12020-018-1607-3. Epub 2018 May 16.

引用本文的文献

1
Pathology diagnosis of intraoperative frozen thyroid lesions assisted by deep learning.深度学习辅助下的甲状腺术中冰冻切片病变的病理学诊断。
BMC Cancer. 2024 Aug 29;24(1):1069. doi: 10.1186/s12885-024-12849-8.
2
The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old.美国甲状腺协会儿童甲状腺癌风险分层在预测≤18 岁甲状腺乳头状癌患者治疗反应中的作用及突变。
J Clin Res Pediatr Endocrinol. 2022 Jun 7;14(2):196-206. doi: 10.4274/jcrpe.galenos.2022.2021-10-4. Epub 2022 Feb 9.
3
Identification of key candidate genes and pathways in follicular variant papillary thyroid carcinoma by integrated bioinformatical analysis.

本文引用的文献

1
Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.滤泡型甲状腺乳头状癌是一种独特的临床实体:基于人群的 10740 例病例研究。
Thyroid. 2013 Oct;23(10):1263-8. doi: 10.1089/thy.2012.0453. Epub 2013 Sep 11.
2
The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes.甲状腺乳头状癌高细胞型:临床病理特征及预后
J Endocrinol Invest. 2013 Apr;36(4):249-54. doi: 10.3275/8515. Epub 2012 Jul 9.
3
The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
通过综合生物信息学分析鉴定滤泡型乳头状甲状腺癌中的关键候选基因和通路
Transl Cancer Res. 2020 Feb;9(2):477-490. doi: 10.21037/tcr.2019.11.38.
4
Radioactive iodine therapy may not improve disease-specific survival in follicular variant papillary thyroid cancer without distant metastasis: A propensity score-matched analysis.放射性碘治疗可能无法提高无远处转移滤泡状甲状腺癌患者的疾病特异性生存率:一项倾向评分匹配分析。
Head Neck. 2021 Jun;43(6):1730-1738. doi: 10.1002/hed.26637. Epub 2021 Feb 9.
5
Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma.对于低至中风险的滤泡状变异型甲状腺乳头状癌患者,使用低剂量放射性碘的消融治疗可能就足够了。
J Int Med Res. 2020 Nov;48(11):300060520966491. doi: 10.1177/0300060520966491.
6
Is a simplified TNM staging system more clinically relevant than the American Joint Committee on Cancer system for the follicular variant of papillary thyroid cancer?对于甲状腺乳头状癌滤泡变体,简化的TNM分期系统是否比美国癌症联合委员会系统更具临床相关性?
Ann Transl Med. 2020 Apr;8(7):463. doi: 10.21037/atm.2020.03.111.
7
A Mobile App for Thyroid Cancer Patients Aiming to Enhance Their Quality of Life: Protocol for a Quasiexperimental Interventional Pilot Study.一款旨在提高甲状腺癌患者生活质量的移动应用程序:一项准实验性干预性初步研究方案。
JMIR Res Protoc. 2020 Mar 13;9(3):e13409. doi: 10.2196/13409.
8
Construction and investigation of lncRNA-associated ceRNA regulatory network in papillary thyroid cancer.构建并探究甲状腺乳头状癌中 lncRNA 相关 ceRNA 调控网络。
Oncol Rep. 2018 Mar;39(3):1197-1206. doi: 10.3892/or.2018.6207. Epub 2018 Jan 10.
9
Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases.甲状腺微小乳头状癌主要不同变体对临床病理特征的影响:1041例研究
Int J Clin Oncol. 2018 Feb;23(1):59-65. doi: 10.1007/s10147-017-1170-6. Epub 2017 Jul 25.
10
Multiple metastasis of follicular variant of papillary thyroid carcinoma coexistent with malignant melanoma.甲状腺乳头状癌滤泡状变异型伴恶性黑色素瘤的多发转移
Korean J Intern Med. 2018 May;33(3):634-637. doi: 10.3904/kjim.2015.309. Epub 2017 Jan 16.
BRAF(V600E) 突变与甲状腺乳头癌预后因素及不良临床结局的相关性:一项荟萃分析。
Cancer. 2012 Apr 1;118(7):1764-73. doi: 10.1002/cncr.26500. Epub 2011 Aug 31.
4
Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation.甲状腺滤泡上皮来源癌中血管侵犯的病理定义及临床意义。
Mod Pathol. 2011 Dec;24(12):1545-52. doi: 10.1038/modpathol.2011.119. Epub 2011 Jul 29.
5
Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.评估全甲状腺切除术和放射性碘残留消融后分化型甲状腺癌的复发风险:使用治疗反应变量来修正新的美国甲状腺协会分期系统预测的初始风险估计。
Thyroid. 2010 Dec;20(12):1341-9. doi: 10.1089/thy.2010.0178. Epub 2010 Oct 29.
6
Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.甲状腺病理学中 BRAF 突变检测的临床影响:作为诊断、预后和治疗应用的潜在用途。
Curr Med Chem. 2010;17(17):1839-50. doi: 10.2174/092986710791111189.
7
Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.甲状腺乳头癌和滤泡癌的分子预后标志物:现状与未来方向。
Mol Cell Endocrinol. 2010 Jun 30;322(1-2):8-28. doi: 10.1016/j.mce.2010.01.007. Epub 2010 Feb 4.
8
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.美国甲状腺协会修订的甲状腺结节和分化型甲状腺癌患者管理指南。
Thyroid. 2009 Nov;19(11):1167-214. doi: 10.1089/thy.2009.0110.
9
BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.日本人群中甲状腺乳头状癌的BRAF突变:其与高危临床病理特征及患者无病生存期缺乏相关性
Endocr J. 2009;56(1):89-97. doi: 10.1507/endocrj.k08e-208. Epub 2008 Oct 8.
10
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.BRAF(V600E)突变与甲状腺乳头状癌患者的预后:一项15年中位随访研究
J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9. doi: 10.1210/jc.2008-0607. Epub 2008 Aug 5.